2-Methylquinoline-4-carboxylic acid

2-Methylquinoline-4-carboxylic acid

 

• CAT Number : Gly-GMSM-122
• CAS Number : 634-38-8 
• Molecular Weight : 187.19
• Molecular Formula : C₁₁H₉NO₂
• Pack size: 10 g

Product description
2-Methylquinoline-4-carboxylic acid is an organic compound with the molecular formula C₁₁H₉NO₂. It features a quinoline core structure with a methyl group at the 2-position and a carboxylic acid group at the 4-position.

Properties

• Molecular weight: 187.19 g/mol
• Chemical formula: C₁₁H₉NO₂
• CAS Number: 634-38-8
• Purity: 90%

Applications and usage

• Used for laboratory research purposes
• Potential applications in pharmaceutical and chemical research
• Its structure makes it useful for various scientific investigations, particularly in the synthesis of biologically active compounds

Safety and handling

• Wear appropriate personal protective equipment
• Handle in a well-ventilated area
• Avoid skin contact, eye contact, and inhalation
• Store in a cool, dry place in a tightly closed container

Involved human diseases

2-Methylquinoline-4-carboxylic acid has shown potential therapeutic effects against several human diseases, particularly in the areas of parasitic infections and cancer:

Antileishmanial Activity

2-Methylquinoline-4-carboxylic acid (Q1) demonstrated promising activity against leishmaniasis, a parasitic disease caused by Leishmania protozoa:

• In a 2019 study, Q1 was found to be the most active compound among 15 synthesized quinoline-4-carboxylic acids against L. donovani promastigotes1.
• The researchers evaluated the IC50 values of these compounds against L. donovani and found Q1 to be the most potent1.
• This suggests potential for developing new antileishmanial drug candidates based on the 2-methylquinoline-4-carboxylic acid scaffold.

Anticancer Properties

While not specific to 2-methylquinoline-4-carboxylic acid, related quinoline-4-carboxylic acid derivatives have shown anticancer activity:

• A series of 2-(4-acrylamidophenyl)-quinoline-4-carboxylic acid derivatives were designed and synthesized as SIRT3 inhibitors for potential cancer treatment2.
• One compound (P6) from this series exhibited potent antiproliferative effects against several leukemia cell lines, including THP-1, MOLM-13, SEM, and MV4-112.
• The compound suppressed colony formation in these leukemia cell lines, indicating its potential as an anticancer agent2.